Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization.

Trial Profile

Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Sep 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms EXCEL
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 31 Oct 2016 Primary endpoint has been met. (Composite measure of all-cause mortality, myocardial infarction (MI) or stroke)
    • 31 Oct 2016 Results published in the New England Journal of Medicine
    • 23 Oct 2014 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top